Doc DEH

Improving Cancer Care is my Passion. My opinions are my Own

[Doc DEH @DocDEHA]

So Honored to attend the @tigerlilycares Gala with my @BeiGeneGlobal colleagues and support their amazing cause. Together united to cure #BreastCancer

[Doc DEH @DocDEHA]

My first week at Beigene and I cannot be more excited about the rich pipeline and the opportunities we have to improve outcomes for people living with cancer #ASCO24 #CancerCare #Beigene

[Doc DEH @DocDEHA]

A full room and a lot of interest at the Pfizer-sponsored symposium ‘Current Advances and Future Opportunities in the treatment of Relapse/Refractory Multiple Myeloma’ at #EHA2023

[Doc DEH @DocDEHA]

What an honor to meet at @ASCO with the distinguished leadership of the @SHAREsupport to discuss how can we best partner to bring the patients’ voices into everything we do @pfizer

[Doc DEH @DocDEHA]

So Proud of our Commentary entitled “Patients at the Heart of the Scientific Dialogue: An Industry Perspective” that just got published online by Oncology and Therapy. Thanks to my Co-authors for their valuable contributions to make this happen.

[Oncology and Therapy @Oncology_Ther]

Authors provide an industry perspective on patient-centricity in the development of medicine, research studies, and publications to aid health literacy and engagement.

Read this commentary here alongside its #PLS: https://t.co/1gtIElhDlx

#patientcentricity #healthliteracy

[Doc DEH @DocDEHA]

Age disparities in #cancer #clinicaltrials remain an issue. An opinion article I authored, published in @sciam, calls on the entire healthcare community to collaborate on solutions to address this disparity and ensure diversity in clinical trials overall.

[Pfizer Inc. @pfizer]

Cancer impacts older adults (65+) the most, yet this group is underrepresented in #clinicaltrials. In this @sciam opinion article, Pfizer Oncology CMO Dany Habr discusses ways to make trial representation more accurate and help improve #cancer care: https://t.co/vS0eV6Ra0w

[Community Oncology @oncologyCOA]

We Must End Ageism in Cancer Clinical Trials - from @sciam @DanyHabr

https://t.co/2i6VVVIXR1

[Doc DEH @DocDEHA]

So good to see the Hematology Team at #EHA2022 and discuss with them and the Hematology Community how we can advance our exciting #Pfizer pipeline for people diagnosed with various Heme Malignancies.

[Doc DEH @DocDEHA]

Everyone felt great to be back and interact again in person with peers and colleagues to advance cancer care and make it more equitable through innovation. #ASCO2022 is a HUGE SUCCESS

[Julie Gralow @jrgralow]

Official #asco22 attendance numbers presented just now at annual @asco business meeting. Record-breaking! 73% in person! So great to have seen you all!

[Pfizer Oncology Medical @PfizerOncMed]

We’re excited to have 26 presentations, including oral presentations on initial safety results for our phase 2 MagnetisMM-3 trial & OS analyses for our phase 3 PALOMA-2 trial, for #ASCO22. Listen to Pfizer Oncology’s CMO, @DanyHabr, discuss our presence this week.

[Doc DEH @DocDEHA]

I don’t know @najat_saliba but from what I heard about her, I felt compelled to vote for her list and I am so happy she won and have a lot of faith in her. Dr Saliba pls unite the non-partisans for a better lebanon for ALL ❤️

[Andy Schmeltz @AndySchmeltz]

Thrilled to share @PCFnews and @pfizer’s Health Equity Challenge Awards, totaling $1.47 million, will support #prostatecancer research that will reduce disparities in the diagnosis, treatment & outcomes of patients in minority and underserved communities. https://t.co/hb7tLS6izk

[Doc DEH @DocDEHA]

So Honored to Support the Breast Cancer Research Foundation
@BCRFcure Hot Pink Party

[Doc DEH @DocDEHA]

Elderly and ethnic minorities are underrepresented in #multiplemyeloma #clinicaltrials even though this disease disproportionately impacts these groups in incidence & outcome. I co-authored an article with @Massimo_Pfizer on how to change this. https://t.co/T8xHbtOowj

[Doc DEH @DocDEHA]

Very Proud of our work in raising awareness on Health Equity in Multiple Myeloma

[Pfizer Oncology Medical @PfizerOncMed]

Ethnic minorities and elderly patients remain underrepresented in #MultipleMyeloma (MM) clinical trials. Read more about potential strategies the pharmaceutical industry could adopt to ensure diversity in trials of emerging MM treatments https://t.co/xyuJHwrOdJ

[Andy Schmeltz @AndySchmeltz]

What incredible news! At @pfizer we are driven by our #patients. We especially value our relationships with the patient organizations we partner with and want to thank each and every one of them for this recognition. #PfizerProud

[Doc DEH @DocDEHA]

Breaking down gender barriers in the workplace can only be achieved through honest, open conversations. By setting tangible goals, created by listening to colleagues, we see real change. I am glad to join the initiative and take action to bring equity one step further. Happy IWD

[Doc DEH @DocDEHA]

@AliTaherMD This outstanding rank is not surprising at all having closely witnessed your dedication, hard work, and pursuit of perfection in science, research, and medicine. Congrats Ali and Thank U for always inspiring us everyday

[Doc DEH @DocDEHA]

Great news on the #EMA approval for our third-generation #ALK-inhibitor for ALK+ advanced #NSCLC! #lungcancer #PfizerProud

[Pfizer Inc. @pfizer_news]

We’re pleased to share that the #EMA approved our third-generation #ALK inhibitor as a first-line treatment for people with ALK-positive advanced #NSCLC. Read more https://t.co/9Xdikz38kY. #lungcancer

[Doc DEH @DocDEHA]

Best Holiday Wishes from our Family to Yours ❤️❤️❤️